What is ENSCW's health score?

Ensysce Biosciences, Inc. (ENSCW) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ENSCW's estimated fair value?

Based on our 5-year discounted cash flow model, Ensysce Biosciences, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ENSCW undervalued or overvalued?

Our model currently rates ENSCW as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ENSCW... Refresh in a moment for the full analysis.

Ensysce Biosciences, Inc. (ENSCW)

Healthcare Fair Value Medium weak

Updated: 2026-04-21

TradeApes Score

reduce

Financial Strength

30 Weak

Operating Trend

40 Weak

Relative Value

48 Mixed

Capital Allocation

30 Weak

Risk

35 Weak

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.